Clinical trial
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected…
NCT00018031 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00018031 |
|---|---|
| Title | Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients |
| Official title | A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin |
| Acronym | HEPCPR |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, HIV Infections |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2b, Ribavirin |
| Enrollment | 36 |
| Start date | Jun 1, 2001 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jun 28, 2001 |
| Last update posted | Oct 1, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: